comparemela.com

Latest Breaking News On - Approval alert - Page 1 : comparemela.com

Pearce IP BioBlast w/e 8 March 2024

On 9 March 2024, Samsung Bioepis presented two papers of study results for its immunology portfolio at the 2024 American Academy of Dermatology (AAD)…

United statesUnited kingdomSan diegoUstekinumab biosimilarsCoherus biosciencesTocilizumab biosimilarSamsung bioepisNovo nordisk ozempicDarzalex fasproFresenius kabi tyenneJanssen stelaraGenentech roche actemraBristol myers squibb opdivoBayer eyleaAmgen xgevaDenosumab biosimilars

Pearce IP BioBlast w/e 26 Jan 2024

AbbVie announced it will invest US$233M in its biologics manufacturing facility in Singapore. The investment will add 24,000L of biologics…

United kingdomSouth koreaUnited statesBayer eyleaSamsung biologicsGenentech avastinSamsung bioepi onbevziCoheru cimerliAlexion solirisGenentech lucentisSamsung bioepisRanibizumab biosimilarRegeneron sanofi dupixentSamsung bioepi episcliCoherus bioscience cimerliChinese national medical products administration

BioBlast w/e 15 Dec 23

Korea Biomed reported that LG Chem’s Xelenka®, biosimilar to AbbVie’s Humira® (adalimumab), has been approved by the Korean Ministry of Food and Drug…

South koreaLendava lendvaSamsung biologicsBiomed nona biosciencesNona biosciencesGenentech avastinSeagen astella padcevCelltrion vegzelmaGenentech actemraAbbvie humiraKorea ministry of foodIntas pharmaceuticalsKorean ministry of foodJapan national health insuranceApproval alertKorean ministry

BioBlast w/e 08 Dec 23

The FDA approved Vertex/CRISPR Therapeutics’ Casgevy® and Bluebird Bio’s Lyfgenia®, the first cell-based gene therapies to treat sickle cell disease…

United statesUnited kingdomBio lyfgeniaAstrazeneca merck lynparzaSamsung bioepi byoovizGenentech lucentisGenentech avastinPolpharma biologicsRoche susvimoBristol myers squibbMerck lynparzaSandoz bio thera avziviHealth canadaEuropean medicines agencyNational institute for healthFirst cell based gene therapies casgevy

BioBlast w/e 17 Nov 23

AstraZeneca (AZ) announced the FDA approved its Truqap® (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients…

Abbvie humiraSamsung bioepisMerck keytrudaAbbvie skyriziRoche tecentriqBristol myers squibbHealth canada approves alvotechEuropean commissionHealth canadaChina national medical products administrationKorean ministry of foodMinistry of foodFrench parliamentEuropean medicines agencyApproval alertTreat advanced

vimarsana © 2020. All Rights Reserved.